A Study of Virtual Reality and Linaclotide for IBS-C
NCT: NCT05796388 · RECRUITING
Brief Summary
The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with linaclotide and sham (placebo) VR therapy.
Frequently Asked Questions
What is A Study of Virtual Reality and Linaclotide for IBS-C?
A Study of Virtual Reality and Linaclotide for IBS-C is a clinical trial registered under NCT05796388. Current status: RECRUITING.
What is the status of NCT05796388?
The current status of NCT05796388 (A Study of Virtual Reality and Linaclotide for IBS-C) is: RECRUITING.
When did A Study of Virtual Reality and Linaclotide for IBS-C start?
A Study of Virtual Reality and Linaclotide for IBS-C started on 2024-05-31.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.